These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38659226)

  • 1. Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study.
    Zhang Y; Qian L; Chen K; Gu S; Meng Z; Wang J; Li Y; Wang P
    Mol Ther; 2024 Jun; 32(6):2000-2020. PubMed ID: 38659226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic virus as an agent for the treatment of malignant ascites.
    Liu HL; Chen J
    Cancer Biother Radiopharm; 2009 Feb; 24(1):99-102. PubMed ID: 19216627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response.
    Zhang Y; Qian L; Chen K; Gu S; Wang J; Meng Z; Li Y; Wang P
    Mol Ther Oncolytics; 2022 Jun; 25():31-42. PubMed ID: 35399603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An oncolytic adenovirus enhances antiangiogenic and antitumoral effects of a replication-deficient adenovirus encoding endostatin by rescuing its selective replication in nasopharyngeal carcinoma cells.
    Liu RY; Zhou L; Zhang YL; Huang BJ; Ke ML; Chen JM; Li LX; Fu X; Wu JX; Huang W
    Biochem Biophys Res Commun; 2013 Dec; 442(3-4):171-6. PubMed ID: 24269822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
    Chen D; Huang L; Zhou H; Zhang Y
    Front Immunol; 2021; 12():615089. PubMed ID: 33717103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
    Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
    J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Tumor Immunogenicity of the Oncolytic Virus CF33-hNIS-antiPDL1 against Ex Vivo Peritoneal Cells from Gastric Cancer Patients.
    Zhang Z; Yang A; Chaurasiya S; Park AK; Kim SI; Lu J; Valencia H; Fong Y; Woo Y
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Liquid Patient Ascites Fluids as a Preclinical Model for Oncolytic Virus Activity.
    Scott EM; Frost S; Khalique H; Freedman JD; Seymour LW; Lei-Rossmann J
    Methods Mol Biol; 2020; 2058():261-270. PubMed ID: 31486044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic Adenovirus H101 Synergizes with Radiation in Cervical Cancer Cells.
    Duan Y; Bai H; Li X; Wang D; Wang Y; Cao M; Zhang N; Chen H; Wang Y
    Curr Cancer Drug Targets; 2021; 21(7):619-630. PubMed ID: 33687882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing the Antitumor Efficacy of Oncolytic Adenovirus Through Sonodynamic Therapy-Augmented Virus Replication.
    Ding J; Su R; Yang R; Xu J; Liu X; Yao T; Li S; Wang C; Zhang H; Yue Q; Zhan C; Li C; Gao X
    ACS Nano; 2024 Jul; 18(28):18282-18298. PubMed ID: 38953884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The spatial and single-cell analysis reveals remodeled immune microenvironment induced by synthetic oncolytic adenovirus treatment.
    Liu G; Hu Q; Peng S; Ning H; Mai J; Chen X; Tao M; Liu Q; Huang H; Jiang Y; Ding Y; Zhang X; Gu J; Xie Z
    Cancer Lett; 2024 Jan; 581():216485. PubMed ID: 38008394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
    Liikanen I; Ahtiainen L; Hirvinen ML; Bramante S; Cerullo V; Nokisalmi P; Hemminki O; Diaconu I; Pesonen S; Koski A; Kangasniemi L; Pesonen SK; Oksanen M; Laasonen L; Partanen K; Joensuu T; Zhao F; Kanerva A; Hemminki A
    Mol Ther; 2013 Jun; 21(6):1212-23. PubMed ID: 23546299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
    Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine.
    Basnet S; Van der Heijden M; Quixabeira DCA; Jirovec E; Grönberg-Vähä-Koskela SAM; Clubb JHA; Kanerva A; Pakola S; Haybout L; Arias V; Hemminki O; Kudling T; Zafar S; Cervera-Carrascon V; Santos JM; Hemminki A
    Mol Ther; 2024 Sep; 32(9):3114-3127. PubMed ID: 38910324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
    Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
    Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
    Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
    Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.
    Lang FF; Conrad C; Gomez-Manzano C; Yung WKA; Sawaya R; Weinberg JS; Prabhu SS; Rao G; Fuller GN; Aldape KD; Gumin J; Vence LM; Wistuba I; Rodriguez-Canales J; Villalobos PA; Dirven CMF; Tejada S; Valle RD; Alonso MM; Ewald B; Peterkin JJ; Tufaro F; Fueyo J
    J Clin Oncol; 2018 May; 36(14):1419-1427. PubMed ID: 29432077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy.
    Niemann J; Woller N; Brooks J; Fleischmann-Mundt B; Martin NT; Kloos A; Knocke S; Ernst AM; Manns MP; Kubicka S; Wirth TC; Gerardy-Schahn R; Kühnel F
    Nat Commun; 2019 Jul; 10(1):3236. PubMed ID: 31324774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines.
    Huang X; Jia R; Zhao X; Liu B; Wang H; Wang J; Zhou Y; Cun B; Ge S; Fan X
    Br J Ophthalmol; 2012 Oct; 96(10):1331-8. PubMed ID: 22843987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
    Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
    Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.